Cost-effectiveness Analysis of Rivaroxaban versus Acenocoumarol in the Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation in Spain
**Objective:** The aim of this study was to evaluate, from the Spanish National Health System perspective, the cost-effectiveness of rivaroxaban (20 mg/day) versus use of acenocoumarol (5 mg/day) for the treatment of patients with non-valvular atrial fibrillation (NVAF) at moderate to high risk for...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | http://jheor.scholasticahq.com/article/9823-cost-effectiveness-analysis-of-rivaroxaban-versus-acenocoumarol-in-the-prevention-of-stroke-in-patients-with-non-valvular-atrial-fibrillation-in-spain.pdf |